Agios Highlights Publication Of TIBSOVO Phase 3 Data In The Lancet Oncology Demonstrating 'Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients'